ADC Therapeutics SA (NYSE:ADCT)
$ 2.93 -0.05 (-1.68%) Market Cap: 283.30 Mil Enterprise Value: 112.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

ADC Therapeutics SA Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine and Camidanlumab Tesirine Conference Call Transcript

Dec 07, 2020 / 01:00PM GMT
Release Date Price: $34.67 (-3.29%)
Operator

Good morning, and welcome to the ADC Therapeutics webcast and conference call highlighting ADC Therapeutics' presentations at the ASH 2020 Virtual Meeting. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn the call over to Amanda Hamilton, Investor Relations Manager.

Amanda Hamilton
ADC Therapeutics SA - IR Officer

Good morning, and welcome to our call. Earlier this morning, we issued a press release announcing our updated clinical data on our lead antibody drug conjugate programs, Lonca and Cami. This release as well as a replay of today's webcast, including slides, will be available on the Investors section of our website at www.adctherapeutics.com.

As a reminder, during today's call, we will be making forward-looking statements. All statements other than statements of historical facts are forward-looking statements. Such statements are subject to risks and uncertainties, and actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot